Photo from wikipedia
ABSTRACT Introduction Currently immunotherapy is considered a cutting edge pharmaceutical treatment for non-small cell lung cancer. Tumor profile plays a crucial role in identifying the correct patient group. Methods Therefore,… Click to show full abstract
ABSTRACT Introduction Currently immunotherapy is considered a cutting edge pharmaceutical treatment for non-small cell lung cancer. Tumor profile plays a crucial role in identifying the correct patient group. Methods Therefore, initial biopsies and re-biopsies are necessary in order to identify the expression of programmed death-ligand-1. Results This information is crucial and therefore all future immunotherapy studies have to be built upon a specific statistical model which associates the tumor profile and tumor profile expression along with treatment efficiency. Discussion We present a novel statistical methodology for future immunotherapy studies of non-small cell lung cancer.
Journal Title: Expert Review of Respiratory Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!